SCHEMBL3622348

SCHEMBL3622348

CC[C@@](N)(C#N)c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.43
SLC6A2 P23975 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
HRH1 P35367 1/20 0.38
HTR2B P41595 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A3 Q01959 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CCR1 P32246 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HIF1A Q16665 1/20 0.33
KIF11 P52732 1/20 0.33
MIF P14174 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3622346 1.00 CYP19A1 (0.43) CYP19A1SLC6A2HTR2ASLC6A4HRH1
SCHEMBL6829587 0.81 KCNN4 (0.34) CYP19A1
SCHEMBL6997314 0.80 CYP2D6 (0.42) SLC6A2NPSR1KIF11
SCHEMBL26688903 0.77 CUL4A (0.33) CYP19A1MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL8445728 0.76 CCR1 (0.43) CYP19A1HTR2ASLC6A4MEN1KMT2A
SCHEMBL1626918 0.74 ESR1 (0.44) CYP19A1SLC6A2HTR2ASLC6A4HRH1
SCHEMBL27897735 0.74 MEN1 (0.46) CYP19A1SLC6A2HTR2ASLC6A4HRH1
Methylene Chloride SCHEMBL27897739 0.73 SLC6A2 (0.47) CYP19A1SLC6A2HTR2ASLC6A4HRH1
SCHEMBL13749516 0.73 CYP19A1 (0.46) CYP19A1SLC6A2HTR2ASLC6A4HRH1
SCHEMBL1546440 0.73 CYP19A1 (0.46) CYP19A1SLC6A2HTR2ASLC6A4HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114906-B1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8604061-B2 2-aminooxazolines as TAAR1 ligands HOFFMANN-LA ROCHE INC. (US) 2013-12-10 US disclosed
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO (DE) 2012-08-02 US disclosed
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS GALLEY GUIDO 2010-05-13 US disclosed
CN-101600700-A Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders HOFFMANN LA ROCHE (CH) 2009-12-09 CN disclosed
EP-2114906-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands F. HOFFMANN-LA ROCHE AG (CH) 2008-10-23 US disclosed
WO-2008092785-A1 NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120864-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R CYP19A1 575/4885SLC6A2 82/4885HTR2A 18/4885
US-20120196903-A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS TAAR1, TAAR5, NPY2R CYP19A1 673/4885SLC6A2 65/4885HTR2A 17/4885
US-20080261920-A1 2-Aminooxazolines as TAAR1 ligands TAAR1, TAAR5, NPY2R CYP19A1 575/4885SLC6A2 82/4885HTR2A 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.